Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003023 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00003023: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00003023 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003023, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody A1G4 with BCG may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody A1G4 plus BCG in treating patients with cancer.
Interventions
- BIOLOGICAL BCG vaccine
- BIOLOGICAL monoclonal antibody A1G4 anti-idiotype vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 1997-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003023
The ClinicalTrials.gov registry entry for NCT00003023 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BCG vaccine is the first listed.
NCT00003023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003023 about?
NCT00003023 is a clinical study titled "Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody A1G4 with BCG may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody A1G4...
What is the current status of trial NCT00003023?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 1997-03.
What interventions are being tested in trial NCT00003023?
The interventions under investigation include: BCG vaccine (BIOLOGICAL), monoclonal antibody A1G4 anti-idiotype vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003023?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.